We’re glad to see you’re enjoying ReachMD…but how about a more personalized experience?
What Is the Future of Neoadjuvant ARI Intensification in Localized Prostate Cancer?
Rana McKay, MD
Opening Statements in the Case of Targeted Versus ICI Adjuvant Treatment of Stage III Melanoma
Jeffrey S. Weber, MD, PhD
Ryan Sullivan, MD
Omid Hamid, MD
Prostate Cancer: Focusing Androgen Receptor Inhibitors on High-Risk Localized & Locally Advanced Disease
Neeraj Agarwal, MD, FASCO
Holding Court in Melanoma: Choosing the Optimal Adjuvant Treatment Approach for Stage III BRAF-Mutant Melanoma
Jason J. Luke, MD, FACP
Sapna Patel, MD
How Are ARIs Being Used to Intensify Therapy for High-Risk Localized Prostate Cancer After Local Therapy?
Defense: Argument for Anti-LAG3-based Frontline Combination ICI Treatment of Stage IV Melanoma
Should We Make Active Surveillance More Active for Localized Prostate Cancer?
Case Study: How Do We Optimize Treatment Adherence with ARIs in Localized Prostate Cancer?
How Do We Identify Patients with Localized Prostate Cancer Who Are at Increased Risk for Developing Metastatic Disease?
Prosecution: Argument for Anti-CTLA-4-based Frontline Combination ICI Treatment of Stage IV Melanoma
Lowering Burden to Raise Adherence: Optimizing Prophylaxis for Hemophilia A
Guy Young, MD
Improving Communication Across Care Settings
Biree Andemariam, MD
Caroline Freiermuth, MD
Why Do We Need New Therapies for Sickle Cell Disease?
A Quick Look at Standard Treatments for Sickle Cell Disease
Sickle Cell Disease Across the Life Span: What Your Patients Want You to Know
Press cancel to remain on ReachMD. Press the link below or the continue button to keep going.
Stay current with the best on medical education